Average activity profiles (left column) and double-plotted actograms (right column) of <i>Marinogammarus marinus</i> (A-B) and <i>Gammarus pulex</i> (C-D) under the LD light regime... by Charlotte N. Underwood (5043110)

Subjects:

Chromatograms presented the specificity of the proposed method. by Ewa Paszkowska (21246702)

Subjects:

Chord plots of the 20 DESRG-enriched GO terms and KEGG pathways. by Wei He (131453)

Subjects:

miR-1247-3p plasmid. by Dequan Wang (6007007)

Subjects:

Molecular docking showed that ABT-199 can fit into active site of ALK^Mutant. by Richard Junior Zapata Dongo (17912565)

Subjects:

Study flowchart. by Wei He (131453)

Subjects:

RNA-sequencing data screening for miR-1247-3p target genes. by Dequan Wang (6007007)

Subjects:

Characteristics and outcomes from clams with MarBTN and control healthy clams. by Rachael M. Giersch (22331947)

Subjects:

The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. by Richard Junior Zapata Dongo (17912565)

Subjects:

Dual luciferase primer. by Dequan Wang (6007007)

Subjects:

Differentially expressed genes following Mod knockdown. by Amalia S. Parra (4173004)

Subjects:

HRV values (Approximately here). by Burhan Demirkıran (21601740)

Subjects:

Twenty differentially expressed senescence-related genes. by Wei He (131453)

Subjects:

shCCND1 plasmid. by Dequan Wang (6007007)

Subjects:

CCND1 promoted chemoresistance in CRC. by Dequan Wang (6007007)

Subjects:

Measuring the Young’s modulus of Hela cells subjected to different durations of fluid shear stress by Atomic Force Microscopy (AFM). by Xinyao Zhao (5824427)

Subjects:

Amino acids interactions and binding energy describe that ABT-199 binds to ALK^Mutant. by Richard Junior Zapata Dongo (17912565)

Subjects:

Visualization of immune cell infiltration between AD and control group. by Wei He (131453)

Subjects:

Correlation between the amount of physical activity recorded PLUS CYCLE^® and video-observed activity. by Akihiro Ohnishi (10989900)

Subjects:

Trial Design (Approximately Here). by Burhan Demirkıran (21601740)

Subjects: